Search

everythinglearnresearchcommunity

for

Search:↓

Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Traditional treatment for pediatric alopecia areata is most effective and should be first choice.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Topical calcipotriol may help treat alopecia areata, especially in those with low vitamin D.

Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Winter-onset alopecia areata patients are more likely to regrow hair within a year compared to spring-onset patients.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

Phototherapy helps some patients with alopecia areata regrow hair, especially those with hair at treatment start and less severe forms of the condition.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Baricitinib is effective and safe for treating alopecia areata in Korea.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Baricitinib is effective for severe alopecia areata but has some side effects.

Alopecia areata severity and symptoms vary by race and ethnicity.

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Pigmented vellus and upright regrowing hairs predict hair regrowth in severe alopecia.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.